Scientific article published about the Phase I clinical trial of the COVID-19 vaccine ABNCoV2
Hørsholm, Denmark, January 20, 2023 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that the journal The Lancet Microbe published an article about the COVID-19 vaccine candidate ABNCoV2 titled “First-in-human use of a modular capsid virus-like vaccine platform: an open-label, non-randomised, phase 1 clinical trial of the SARS-CoV-2 vaccine ABNCoV2” co-authored by ExpreS2ion scientists.
Abstract excerpt: “Immunisation with ABNCoV2 was well tolerated, safe, and resulted in a functional immune response. The data support the need for additional clinical development of ABNCoV2 as a second-generation SARS-CoV-2 vaccine. The modular cVLP platform will accelerate vaccine development, beyond SARS-CoV-2.”
This publication is a result of the close research collaboration in the COUGH-1 trial study group under the Prevent-nCoV consortium as announced in August 2021 and November 2021.
The scientific article reference: Merel J Smit; Adam F Sander; Maud B P A Ariaans; Cyrielle Fougeroux; Constanze Heinzel; Rolf Fendel; Meral Esen; Peter G Kremsner; Rob ter Heine; Heiman F Wertheim; Manja Idorn; Søren Riis Paludan; Alexander P Underwood; Alekxander Binderup; Santseharay Ramirez; Jens Bukh; Max Soegaard; Sayit M Erdogan; Tobias Gustavsson; Stine Clemmensen; Thor G Theander; Ali Salanti; Mette Hamborg; Willem A de Jongh; Matthew B B McCall; Morten A Nielsen; Benjamin G Mordmüller; Robert Dagil; Louise Goksøyr; Thomas M Hulen; Christoph Janitzek; Daniel S Jensen; Sune Justesen; Paul K Khalifé; Andrea Kreidenweiss; Telma Lança; Olivia Lie-Andersen; Karina Teelen; Elena Vidal-Calvo. First-in-human use of a modular capsid virus-like vaccine platform: an open-label, non-randomised, phase 1 clinical trial of the SARS-CoV-2 vaccine ABNCoV2. The Lancet Microbe. 2023 - https://doi.org/10.1016/S2666-5247(22)00337-8. The article can also be found via this link, as well as via the Research Publications page of ExpreS2ion’s website.
Certified Adviser
Svensk Kapitalmarknadsgranskning AB
For further information about ExpreS2ion Biotech Holding AB, please contact:
Bent U. Frandsen, CEO
Telephone: +45 4256 6869
E-mail: buf@expres2ionbio.com
Keith Alexander, CFO
Telephone: +45 5131 8147
E-mail: ka@expres2ionbio.com
About ExpreS2ion
ExpreS2ion Biotechnologies ApS is a fully owned Danish subsidiary of ExpreS2ion Biotech Holding AB with company register number 559033-3729. ExpreS2ion has developed a unique technology platform, ExpreS2, for fast and efficient non-clinical development and production of complex proteins for new vaccines and diagnostics. ExpreS2 is regulatorily validated for clinical supply. The platform includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Since 2010, the Company has produced more than 500 proteins and virus-like particles (VLPs) in collaboration with leading research institutions and companies. ExpreS2ion develops novel VLP based vaccines in association with AdaptVac ApS, of which ExpreS2ion owns 34%. For additional information, please visit www.expres2ionbio.com.
Tags: